top of page

Introducing 428Pharma.

The Right Medication to the Right Patient

Our Story

A team of former senior directors from big pharma with combined 60+ years and more than 60 projects in diagnostics and 505(b)(2) drug development have secured exclusive worldwide rights to a high value asset, made available by a recent well-publicized R&D restructuring and divestment.

Our Portfolio

Escitalopram LAI (Long Acting Injectable)

An early stage asset at formulation stage.  With the discovery and patenting of a novel salt to Escitalopram we can bring the first SSRI depot to the market.


  • First depot injection for SSRI for a vast depression market estimated at $15.8Bn in 2025

  • 505(b)(2) truncated development with LOE Q4 2038.  Opportunity to out-license end of phase I

  • Estimated potential peak sales of over $1.5Bn (US and EU big 5)


Why 428 Pharma?

Experienced pharma team with over 60 projects between the team in the area of diagnostics and 505(b)(2) drug development

Get in Touch

+972 (0) 54 888 5275

Thanks for submitting!

bottom of page